Get the Stockscreener App
4.85
0.72%
-0.035
Imagenebio Inc stock is traded at $4.85, with a volume of 15,462.
It is down -0.72% in the last 24 hours and down -15.06% over the past month.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
See More
Previous Close:
$4.885
Open:
$4.865
24h Volume:
15,462
Relative Volume:
1.26
Market Cap:
$55.05M
Revenue:
$800.00K
Net Income/Loss:
$-45.07M
P/E Ratio:
-0.9224
EPS:
-5.2583
Net Cash Flow:
$-52.08M
1W Performance:
-9.18%
1M Performance:
-15.06%
6M Performance:
-21.14%
1Y Performance:
-42.60%
1-Day Range:
$4.73
$4.97
1-Week Range:
$4.73
$5.54
52-Week Range:
$3.94
$9.4734
Imagenebio Inc Stock (IMA) Company Profile
Name
Imagenebio Inc
Sector
Industry
Phone
857-343-8292
Address
12526 HIGH BLUFF DRIVE, SAN DIEGO
Compare IMA vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
4.85 | 63.68M | 800.00K | -45.07M | -52.08M | -5.2583 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Resumed | Wedbush | Underperform |
| Oct-24-25 | Initiated | Leerink Partners | Outperform |
Imagenebio Inc Stock (IMA) Latest News
ImageneBio, Inc. (NASDAQ:IMA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
HC Wainwright Initiates ImageneBio at Buy With $28 Price Target - marketscreener.com
Blue Owl Capital Holdings LP Invests $5.41 Million in ImageneBio, Inc. $IMA - MarketBeat
ImageneBio (NASDAQ:IMA) Trading 1.8% HigherWhat's Next? - MarketBeat
ImageneBio Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
ImageneBio (IMA) shifts CFO equity mix toward RSUs in new grant - Stock Titan
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
ImageneBio's New Hires Get Stock Awards as CFO Gets a Separate Award - Stock Titan
ImageneBio, Inc. (NASDAQ: IMA) Share Price, IMA Stock News, IMA Share Price & Updates - Kalkine
ImageneBio, Inc. (IMA): BVF group discloses 9.99% stake and large warrants - Stock Titan
ImageneBio, Inc. SEC Filing (Aug 12, 2026) - Stock Titan
IMA Stock Surges 24%, Breaks 50-DMA For First Time Since February – What's Driving The Rally? - Stocktwits
ImageneBio Ord Shs (IMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ImageneBio, Inc. SEC Filing (Aug 7, 2026) - Stock Titan
Wedbush Maintains ImageneBio(IMA.US) With Sell Rating, Maintains Target Price $2 - Moomoo
William Blair Maintains ImageneBio(IMA.US) With Buy Rating - Moomoo
ImageneBio (IMA) registers 1.37M existing shares for resale on Form S-3 - Stock Titan
ImageneBio (IMA) sets up $200M shelf and $17M ATM stock program - Stock Titan
ImageneBio (IMA) files to register 5.77M warrant shares for investor resale - Stock Titan
ImageneBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ImageneBio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ImageneBio Sees Cash Runway Funding Planned Ops Into 1Q of 2028 >IMA - Moomoo
ImageneBio, Inc. Q2 2026: Revenue $0 EPS $(0.63) — 10-Q Summary - TradingView
ImageneBio Reports Second Quarter 2026 Financial Results and Corporate Update on Olevaprubart Clinical Development - Quiver Quantitative
ImageneBio reports Q2 2026: $136.2M cash; $10.2M net loss for quarter - TradingView
ImageneBio Posts $10.2 Million Q2 Loss With Cash Runway Into 2028 - Quiver Quantitative
ImageneBio (Nasdaq: IMA) details Q2 2026 loss and $136M cash runway - Stock Titan
IMA: Clinical pipeline advances and robust cash position support continued development through 2028 - TradingView
ImageneBio’s Atopic Dermatitis Data Anticipated in Q4 2027 - Stock Titan
IKNA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
IMA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
ImageneBio, Inc. Revenue Breakdown – NASDAQ:IMA - TradingView
ImageneBio Inc. (IMA) Q1 2026 Earnings: EPS Miss Highlights Pre‑Revenue Challenges as Stock Rises - dars.gov.et
ImageneBio (NASDAQ:IMA) Trading Up 2.9%Should You Buy? - MarketBeat
ImageneBio Ord Shs (IMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IMA|ImageneBio Ord Shs|Price:5.600| - TradingKey
ImageneBio, Inc. Revenue Breakdown – BOATS:IMA - TradingView
ImageneBio Inc. (IMA) Q1 2026 Earnings: EPS Misses Estimates Amid Continued R&D InvestmentRevenue Surprise History - dars.gov.et
ImageneBio Inc. (IMA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
ImageneBio Strengthens Leadership with New CFO Appointment - TipRanks
ImageneBio (IMA) hires CFO with $450,000 salary and equity awards - Stock Titan
Imagenebio, Inc. Appoints Yanina Grant-Huerta as Chief Financial Officer, Effective July 20, 2026 - marketscreener.com
IMA Q1 2026 Earnings: Wider-Than-Expected Loss Reflects Continued R&D InvestmentOperating Margin Analysis - vinanet.vn
Form 4 ImageneBio Inc For: 21 July By Investing.com - Investing.com South Africa
ImageneBio principal accounting officer sells $17,334 in stock By Investing.com - Investing.com Nigeria
ImageneBio principal accounting officer sells $17,334 in stock - Investing.com
Insider Sell: Robert Lally Sells Shares of ImageneBio Inc (IMA) - GuruFocus
ImageneBio Principal Accounting Officer Robert B. Lally sells USD 17,350 of common shares - Bitget
ImageneBio (IMA) accounting chief sells 3,196 shares in July trades - Stock Titan
Insider Buyers Lose Additional US$9.8k As ImageneBio Dips To US$61m - simplywall.st
ImageneBio, Inc. Financial Disclosures & SEC Filings - TradingView
Imagenebio Inc Stock (IMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Imagenebio Inc Stock (IMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lally Robert B | Principal Accounting Officer |
Jul 16 '26 |
Sale |
5.50 |
1,671 |
9,190 |
57,107 |
| Lally Robert B | Principal Accounting Officer |
Jul 17 '26 |
Sale |
5.34 |
1,525 |
8,144 |
55,582 |
| SLATTERY JOSEPH P | Director |
Dec 24 '25 |
Buy |
5.99 |
16,000 |
95,840 |
16,000 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):